Rosiglitazone Alleviates Mechanical Allodynia of Rats with Bone Cancer Pain through the Activation of PPAR-γ to Inhibit the NF-κB/NLRP3 Inflammatory Axis in Spinal Cord Neurons
Bone cancer pain (BCP) is a serious clinical problem that affects the quality of life of cancer patients. However, the current treatment methods for this condition are still unsatisfactory. This study investigated whether intrathecal injection of rosiglitazone modulates the noxious behaviors associa...
Saved in:
Main Authors: | Jie Fu, Baoxia Zhao, Chaobo Ni, Huadong Ni, Longsheng Xu, Qiuli He, Miao Xu, Chengfei Xu, Ge Luo, Jianjun Zhu, Jiachun Tao, Ming Yao |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | PPAR Research |
Online Access: | http://dx.doi.org/10.1155/2021/6086265 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Influence of Rosiglitazone on the Expression of PPARγ, NF-κB, and TNF-α in Rat Model of Ulcerative Colitis
by: Jing-Wei Mao, et al.
Published: (2012-01-01) -
Rosiglitazone Restores Endothelial Dysfunction in a Rat Model of Metabolic Syndrome through PPARγ- and PPARδ-Dependent Phosphorylation of Akt and eNOS
by: Zhigang Zhao, et al.
Published: (2011-01-01) -
Expression of GPR43 in Brown Adipogenesis Is Enhanced by Rosiglitazone and Controlled by PPARγ/RXR Heterodimerization
by: Jiamiao Hu, et al.
Published: (2018-01-01) -
The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects
by: Galina S. Bogatkevich, et al.
Published: (2012-01-01) -
Rosiglitazone, a Ligand to PPARγ, Improves Blood Pressure and Vascular Function through Renin-Angiotensin System Regulation
by: María Sánchez-Aguilar, et al.
Published: (2019-01-01)